Scintigraphic load of bone disease evaluated by DASciS software as a survival predictor in metastatic castration-resistant prostate cancer patients candidates to 223RaCl treatment
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.
Den RB, George D, Pieczonka C, McNamara M. Ra-223 treatment for bone metastases in castrate-resistant prostate cancer: practical management issues for patient selection. Am J Clin Oncol 2019; 42: 399-406. doi: 10.1097/coc.0000000000000528DenRBGeorgeDPieczonkaCMcNamaraMRa-223 treatment for bone metastases in castrate-resistant prostate cancer: practical management issues for patient selectionAm J Clin Oncol20194239940610.1097/coc.0000000000000528644561330844849Open DOISearch in Google Scholar
De Vincentis G, Gerritsen W, Gschwend JE, Hacker M, Lewington V, O’Sullivan JM, et al. Advances in targeted alpha therapy for prostate cancer. Ann Oncol 2019; 0: 1-12. doi: 10.1093/annonc/mdz270De VincentisGGerritsenWGschwendJEHackerMLewingtonVO’SullivanJMAdvances in targeted alpha therapy for prostate cancerAnn Oncol2019011210.1093/annonc/mdz270692731431418764Open DOISearch in Google Scholar
Logothetis C, Morris MJ, Den R, Coleman RE. Current perspectives on bone metastases in castrate-resistant prostate cancer. Cancer Metastasis Rev 2018; 37: 189-96. doi: 10.1007/s10555-017-9719-4LogothetisCMorrisMJDenRColemanRECurrent perspectives on bone metastases in castrate-resistant prostate cancerCancer Metastasis Rev2018371899610.1007/s10555-017-9719-4580138729380085Open DOISearch in Google Scholar
Bruland OS, Nilsson S, Fisher DR, Larsen RH. High-linear energy transfer irradiation targeted to skeletal metastases by the alpha-emitter 223Ra: adjuvant or alternative to conventional modalities? Clin Cancer Res 2006; 12: 6250s-7s. doi: 10.1158/1078-0432.ccr-06-0841BrulandOSNilssonSFisherDRLarsenRHHigh-linear energy transfer irradiation targeted to skeletal metastases by the alpha-emitter 223Ra: adjuvant or alternative to conventional modalities?Clin Cancer Res2006126250s7s10.1158/1078-0432.ccr-06-084117062709Open DOISearch in Google Scholar
Henriksen G, Fisher DR, Roeske JC, Bruland OS, Larsen RH. Targeting of osseous sites with alpha-emitting 223Ra: comparison with the beta-emitter 89Sr in mice. J Nucl Med 2003; 44: 252-9. PMID: 12571218HenriksenGFisherDRRoeskeJCBrulandOSLarsenRHTargeting of osseous sites with alpha-emitting 223Ra: comparison with the beta-emitter 89Sr in miceJ Nucl Med2003442529PMID: 12571218Search in Google Scholar
De Vincentis G, Follacchio GA, Frantellizzi V, Prelaj A, Farcomeni A, Giuli A, et al. 223Ra-dichloride therapy in an elderly bone metastatic castration-resistant prostate cancer patient: a case report presentation and comparison with existing literature. Aging Clin Exp Res 2017; 30: 677-80. doi: 10.1007/s40520-017-0826-4De VincentisGFollacchioGAFrantellizziVPrelajAFarcomeniAGiuliA223Ra-dichloride therapy in an elderly bone metastatic castration-resistant prostate cancer patient: a case report presentation and comparison with existing literatureAging Clin Exp Res2017306778010.1007/s40520-017-0826-428856577Open DOISearch in Google Scholar
De Vincentis G, Monari F, Baldari S, Salgarello M, Frantellizzi V, Salvi E, et al. Narrative medicine in metastatic prostate cancer reveals ways to improve patient awareness & quality of care. Future Oncol 2018; 14: 2821-32. doi: 10.2217/fon-2018-0318De VincentisGMonariFBaldariSSalgarelloMFrantellizziVSalviENarrative medicine in metastatic prostate cancer reveals ways to improve patient awareness & quality of careFuture Oncol20181428213210.2217/fon-2018-031829905090Open DOISearch in Google Scholar
De Vincentis G, Frantellizzi V, Follacchio GA, Farcomeni A, Pani A, Samaritani R,et al. No evidence of association between psychological distress and pain relief in patients with bone metastases from castration-resistant prostate cancer treated with 223Radium. Eur J Cancer Care 2019; 28: e13112. doi: 10.1111/ecc.13112De VincentisGFrantellizziVFollacchioGAFarcomeniAPaniASamaritaniRNo evidence of association between psychological distress and pain relief in patients with bone metastases from castration-resistant prostate cancer treated with 223RadiumEur J Cancer Care201928e1311210.1111/ecc.1311231148330Open DOISearch in Google Scholar
Lecouvet FE, Talbot JN, Messiou C, Bourguet P, Liu Y, de Souza NM. Monitoring the response of bone metastases to treatment with Magnetic Resonance Imaging and nuclear medicine techniques: a review and position statement by the European Organisation for Research and Treatment of Cancer imaging group. Eur J Cancer 2014; 50: 2519-31. doi: 10.1016/j.ejca.2014.07.002LecouvetFETalbotJNMessiouCBourguetPLiuYde SouzaNMMonitoring the response of bone metastases to treatment with Magnetic Resonance Imaging and nuclear medicine techniques: a review and position statement by the European Organisation for Research and Treatment of Cancer imaging groupEur J Cancer20145025193110.1016/j.ejca.2014.07.00225139492Open DOISearch in Google Scholar
Pyka T, Okamoto S, Dahlbender M, Tauber R, Retz M, Heck M, et al. Comparison of bone scintigraphy and (68)Ga-PSMA PET for skeletal staging in prostate cancer. Eur J Nucl Med Mol Imaging 2016; 43: 2114-21. doi: 10.1007/s00259-016-3435-0PykaTOkamotoSDahlbenderMTauberRRetzMHeckMComparison of bone scintigraphy and (68)Ga-PSMA PET for skeletal staging in prostate cancerEur J Nucl Med Mol Imaging20164321142110.1007/s00259-016-3435-027290607Open DOISearch in Google Scholar
Scher HI, Halabi S, Tannock I, Morris M, Sternberg CN, Carducci MA, et al. Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. J Clin Oncol 2008; 26: 1148-59. doi: 10.1200/jco.2007.12.4487ScherHIHalabiSTannockIMorrisMSternbergCNCarducciMADesign and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working GroupJ Clin Oncol20082611485910.1200/jco.2007.12.4487Open DOISearch in Google Scholar
Dennis ER, Jia X, Mezheritskiy IS, Stephenson RD, Schoder H, Fox JJ, et al. Bone scan index: a quantitative treatment response biomarker for castration-resistant metastatic prostate cancer J Clin Oncol 2012; 30: 519-24. doi: 10.1200/jco.2011.36.5791DennisERJiaXMezheritskiyISStephensonRDSchoderHFoxJJBone scan index: a quantitative treatment response biomarker for castration-resistant metastatic prostate cancerJ Clin Oncol2012305192410.1200/jco.2011.36.5791Open DOISearch in Google Scholar
Anand A, Morris MJ, Larson SM, Minarik D, Josefsson A, Helgstrand JT, et al. Automated Bone Scan Index as a quantitative imaging biomarker in metastatic castration-resistant prostate cancer patients being treated with enzalutamide. EJNMMI Res 2016; 6: 23. doi: 10.1186/s13550-016-0173-zAnandAMorrisMJLarsonSMMinarikDJosefssonAHelgstrandJTAutomated Bone Scan Index as a quantitative imaging biomarker in metastatic castration-resistant prostate cancer patients being treated with enzalutamideEJNMMI Res201662310.1186/s13550-016-0173-zOpen DOISearch in Google Scholar
Fosbol MO, Petersen PM, Kjaer A, Mortensen J. (223)Ra therapy of advanced metastatic castration-resistant prostate cancer: quantitative assessment of skeletal tumor burden for prognostication of clinical outcome and hematologic toxicity. J Nucl Med 2018; 59: 596-602. doi: 10.2967/jnumed.117.195677FosbolMOPetersenPMKjaerAMortensenJ(223)Ra therapy of advanced metastatic castration-resistant prostate cancer: quantitative assessment of skeletal tumor burden for prognostication of clinical outcome and hematologic toxicityJ Nucl Med20185959660210.2967/jnumed.117.195677Open DOISearch in Google Scholar
Uemura K, Miyoshi Y, Kawahara T, Yoneyama S, Hattori Y, Teranishi J, et al. Prognostic value of a computer-aided diagnosis system involving bone scans among men treated with docetaxel for metastatic castration-resistant prostate cancer. BMC Cancer 2016; 16: 109. doi: 10.1186/s12885-016-2160-1UemuraKMiyoshiYKawaharaTYoneyamaSHattoriYTeranishiJPrognostic value of a computer-aided diagnosis system involving bone scans among men treated with docetaxel for metastatic castration-resistant prostate cancerBMC Cancer20161610910.1186/s12885-016-2160-1Open DOISearch in Google Scholar
Frantellizzi V, Farcomeni A, Follacchio GA, Pacilio M, Pellegrini R, Pani R, et al. A 3-variable prognostic score (3-PS) for overall survival prediction in metastatic castration-resistant prostate cancer treated with 223Radium-dichloride. Ann Nuc Med 2017; 32: 142-8. doi: 10.1007/s12149-017-1228-6FrantellizziVFarcomeniAFollacchioGAPacilioMPellegriniRPaniRA 3-variable prognostic score (3-PS) for overall survival prediction in metastatic castration-resistant prostate cancer treated with 223Radium-dichlorideAnn Nuc Med201732142810.1007/s12149-017-1228-6Open DOISearch in Google Scholar
Ricci M, Frantellizzi V, Bulzonetti N, De Vincentis G. Reversibility of castration resistance status after Radium-223 dichloride treatment: clinical evidence and review of the literature. Int J Radiat Biol 2019; 95: 554-61. doi: 10.1080/09553002.2019.1558301RicciMFrantellizziVBulzonettiNDe VincentisGReversibility of castration resistance status after Radium-223 dichloride treatment: clinical evidence and review of the literatureInt J Radiat Biol2019955546110.1080/09553002.2019.1558301Open DOISearch in Google Scholar
Baldari S, Boni G, Bortolus R, Caffo O, Conti G, De Vincentis G, et al. Management of metastatic castration-resistant prostate cancer: a focus on radium-223: opinions and suggestions from an expert multidisciplinary panel. Crit Rev Oncol Hematol 2017; 113: 43-51. doi: 10.1016/j.critrevonc.2017.03.001BaldariSBoniGBortolusRCaffoOContiGDe VincentisGManagement of metastatic castration-resistant prostate cancer: a focus on radium-223: opinions and suggestions from an expert multidisciplinary panelCrit Rev Oncol Hematol2017113435110.1016/j.critrevonc.2017.03.001Open DOISearch in Google Scholar
Van den Wyngaert T, Strobel K, Kampen WU, Kuwert T, van der Bruggen W, Mohan HK, et al. The EANM practice guidelines for bone scintigraphy. Eur J Nucl Med Mol Imaging 2016; 43: 1723-38. doi: 10.1007/s00259-016-3415-4Vanden Wyngaert TStrobelKKampenWUKuwertTvan derBruggen WMohanHKThe EANM practice guidelines for bone scintigraphyEur J Nucl Med Mol Imaging20164317233810.1007/s00259-016-3415-4Open DOISearch in Google Scholar
Bradski G. The OpenCV Library. Dr Dobb’s Journal of Software Tools 2000; 120: 122-5. doi: citeulike-article-id:2236121BradskiGThe OpenCV LibraryDr Dobb’s Journal of Software Tools20001201225citeulike-article-id:2236121Open DOISearch in Google Scholar
Suzuki S. Topological structural analysis of digitized binary images by border following. Comput Vision, Graphics Image Process 1985; 30: 32-46. doi: 10.1016/0734-189X(85)90016-7SuzukiSTopological structural analysis of digitized binary images by border followingComput Vision, Graphics Image Process198530324610.1016/0734-189X(85)90016-7Open DOISearch in Google Scholar
Green G. An Essay on the application of mathematical analysis to the theories of electricity and magnetism. Journal fur die Reine und Angewandte Mathematik 1854; 1854: 161-221. doi: 10.1515/crll.1854.47.161GreenGAn Essay on the application of mathematical analysis to the theories of electricity and magnetismJournal fur die Reine und Angewandte Mathematik1854185416122110.1515/crll.1854.47.161Open DOISearch in Google Scholar
Du Y, Carrio I, De Vincentis G, Fanti S, Ilhan H, Mommsen C, et al. Practical recommendations for radium-223 treatment of metastatic castration-resistant prostate cancer. Eur J Nuc Med Mol Imaging 2017; 44: 1671-8. doi: 10.1007/s00259-017-3756-7DuYCarrioIDe VincentisGFantiSIlhanHMommsenCPractical recommendations for radium-223 treatment of metastatic castration-resistant prostate cancerEur J Nuc Med Mol Imaging2017441671810.1007/s00259-017-3756-7553732528631036Open DOISearch in Google Scholar
Osvaldo GF, Salvador MS, Zael SR, Nora SM. Radium-223 in metastatic hormone-sensitive high-grade prostate cancer: initial experience. Am J Nucl Med Mol Imaging 2017; 7: 236-45. PMID: 29181271OsvaldoGFSalvadorMSZaelSRNoraSMRadium-223 in metastatic hormone-sensitive high-grade prostate cancer: initial experienceAm J Nucl Med Mol Imaging2017723645PMID: 29181271Search in Google Scholar
Castello A, Macapinlac HA, Lopci E, Santos EB. Prostate-specific antigen flare induced by 223RaCl2 in patients with metastatic castration-resistant prostate cancer. Eur J Nucl Med Mol Imaging 2018; 45: 2256-63. doi: 10.1007/ s00259-018-4051-yCastelloAMacapinlacHALopciESantosEBProstate-specific antigen flare induced by 223RaCl2 in patients with metastatic castration-resistant prostate cancerEur J Nucl Med Mol Imaging20184522566310.1007/s00259-018-4051-y29785515Open DOISearch in Google Scholar
De Vincentis G, Follacchio GA, Frantellizzi V, Liberatore M, Monteleone F, Cortesi E. Prostate-Specific Antigen flare phenomenon during 223Radichloride treatment for bone metastatic Castration-Resistant Prostate Cancer: a case report. Clin Genitourin Cancer 2016; 14: e529-e533. doi: 10.1016/j.clgc.2016.04.014De VincentisGFollacchioGAFrantellizziVLiberatoreMMonteleoneFCortesiEProstate-Specific Antigen flare phenomenon during 223Radichloride treatment for bone metastatic Castration-Resistant Prostate Cancer: a case reportClin Genitourin Cancer201614e529e53310.1016/j.clgc.2016.04.01427212044Open DOISearch in Google Scholar
Sartor O, Coleman RE, Nilsson S, Heinrich D, Helle SI, O’Sullivan JM, et al. An exploratory analysis of alkaline phosphatase, lactate dehydrogenase, and prostate-specific antigen dynamics in the phase 3 ALSYMPCA trial with radium-223. Ann Oncol 2017; 28: 1090-7. doi: 10.1093/annonc/mdx044SartorOColemanRENilssonSHeinrichDHelleSIO’SullivanJMAn exploratory analysis of alkaline phosphatase, lactate dehydrogenase, and prostate-specific antigen dynamics in the phase 3 ALSYMPCA trial with radium-223Ann Oncol2017281090710.1093/annonc/mdx044540675428453701Open DOISearch in Google Scholar
Heinrich D, Bruland O, Guise TA, Suzuki H, Sartor O. Alkaline phosphatase in metastatic castration-resistant prostate cancer: reassessment of an older biomarker. Future Oncol 2018; 14: 2543-2556. doi: 10.2217/fon-2018-0087HeinrichDBrulandOGuiseTASuzukiHSartorOAlkaline phosphatase in metastatic castration-resistant prostate cancer: reassessment of an older biomarkerFuture Oncol2018142543255610.2217/fon-2018-008729925281Open DOISearch in Google Scholar
Gravis G, Boher J-M, Fizazi K, Joly F, Priou F, Marino P, et al. Prognostic factors for survival in noncastrate metastatic prostate cancer: validation of the glass model and development of a novel simplified prognostic model. Eur Urol 2015; 68: 196-204. doi: 10.1016/j.eururo.2014.09.022GravisGBoherJ-MFizaziKJolyFPriouFMarinoPPrognostic factors for survival in noncastrate metastatic prostate cancer: validation of the glass model and development of a novel simplified prognostic modelEur Urol20156819620410.1016/j.eururo.2014.09.02225277272Open DOISearch in Google Scholar
Parker C, Nilsson S, Heinrich D, Helle SI, O’Sullivan JM, Fosså SD, et al. Alpha emitter Radium-223 and survival in metastatic prostate cancer. N Eng J Med 2013; 369: 213-23. doi: 10.1056/nejmoa1213755ParkerCNilssonSHeinrichDHelleSIO’SullivanJMFossåSDAlpha emitter Radium-223 and survival in metastatic prostate cancerN Eng J Med20133692132310.1056/nejmoa121375523863050Open DOISearch in Google Scholar
Liu Y, Sheng J, Dong Z, Xu Y, Huang Q, Pan D, et al. The diagnostic performance of (18)F-fluoride PET/CT in bone metastases detection: a meta-analysis. Clin Radiol 2019; 74: 196-206. doi: 10.1016/j.crad.2018.12.011LiuYShengJDongZXuYHuangQPanDThe diagnostic performance of (18)F-fluoride PET/CT in bone metastases detection: a meta-analysisClin Radiol20197419620610.1016/j.crad.2018.12.01130648535Open DOISearch in Google Scholar
Sabbatini P, Larson SM, Kremer A, Zhang ZF, Sun M, Yeung H, et al. Prognostic significance of extent of disease in bone in patients with androgen-independent prostate cancer. J Clin Oncol 1999; 17: 948-57. doi: 10.1200/JCO.1999.17.3.948SabbatiniPLarsonSMKremerAZhangZFSunMYeungHPrognostic significance of extent of disease in bone in patients with androgen-independent prostate cancerJ Clin Oncol1999179485710.1200/JCO.1999.17.3.94810071289Open DOISearch in Google Scholar
Smith M, Parker C, Saad F, Miller K, Tombal B, Ng QS, et al. Addition of radium-223 to abiraterone acetate and prednisone or prednisolone in patients with castration-resistant prostate cancer and bone metastases (ERA 223): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol 2019; 20: 408-419. doi: 10.1016/s1470-2045(18)30860-xSmithMParkerCSaadFMillerKTombalBNgQSAddition of radium-223 to abiraterone acetate and prednisone or prednisolone in patients with castration-resistant prostate cancer and bone metastases (ERA 223): a randomised, double-blind, placebo-controlled, phase 3 trialLancet Oncol20192040841910.1016/s1470-2045(18)30860-xOpen DOISearch in Google Scholar
O’Sullivan JM, Heinrich D, James ND, Nilsson S, Ost P, Parker CC, et al. The case against the European Medicines Agency’s change to the label for Radium-223 for the treatment of metastatic castration-resistant prostate cancer. Eur Urol 2018. 75: e51-2. doi: 10.1016/j.eururo.2018.11.003O’SullivanJMHeinrichDJamesNDNilssonSOstPParkerCCThe case against the European Medicines Agency’s change to the label for Radium-223 for the treatment of metastatic castration-resistant prostate cancerEur Urol201875e51210.1016/j.eururo.2018.11.00330454914Open DOISearch in Google Scholar
van der Doelen MJ, Mehra N, Hermsen R, Janssen MJR, Gerritsen WR, van Oort IM. Patient selection for Radium-223 therapy in patients with bone metastatic castration-resistant prostate cancer: new recommendations and future perspectives. Clin Genitourin Cancer 2019; 17: 79-87. doi: 10.1016/j.clgc.2018.11.008van der DoelenMJMehraNHermsenRJanssenMJRGerritsenWRvan OortIMPatient selection for Radium-223 therapy in patients with bone metastatic castration-resistant prostate cancer: new recommendations and future perspectivesClin Genitourin Cancer201917798710.1016/j.clgc.2018.11.00830558834Open DOISearch in Google Scholar
